The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
ApexOnco Front Page
Recent articles
J&J decides not to opt in to erzotabart, and Genmab pulls the plug.
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
Just when investors thought things couldn't get any worse, they do.
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
In first-line breast cancer vepdegestrant will be combined with Pfizer’s investigational CDK4 inhibitor atirmociclib.
